Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06422715Active Not Recruiting

PTLD: Multicentric Retrospective Study

Role: collaborator

NCT04388384Completed

Real-life Pan-HER-blockade With Neratinib

Role: collaborator

NCT04318405Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

Role: lead

NCT04673955Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Role: collaborator

NCT04045691Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Role: collaborator

All 5 trials loaded